Merck & Co – known as MSD outside the US and Canada – has announced its plans to initiate a new phase 3 clinical programme ...
Gilead Sciences (Gilead) has announced the completion of the previously announced transaction to acquire UK-based ...
The approval is specifically for Ultomiris as a treatment for adult patients who are anti-acetylcholine receptor (AChR) ...
AstraZeneca’s (AZ) Tezspire (tezepelumab) has been granted marketing authorisation in Great Britain by the Medicines and Healthcare products Regulatory Agency (MHRA) for use as an add-on maintenance ...
On July 23rd 2022, the World Health Organisation declared Monkeypox a public health emergency of international concern. The outbreak, which dominated the headlines of national newspapers, was ...
Tezspire (tezepelumab) has been approved by the European Commission (EC) for use as an add-on maintenance treatment in ...
Pfizer and Sangamo Therapeutics have reopened the recruitment of their phase 3 study evaluating giroctocogene fitelparvovec, an investigational gene therapy for patients with moderately severe to ...
Bristol Myers Squibb (BMS) has announced positive results from a phase 3 trial evaluating Opdivo (nivolumab) as a single ...
BeiGene has shared that the National Institute for Health and Care Excellence (NICE) has recommended Brukinsa (zanubrutinib) for the treatment of Waldenström’s macroglobulinemia (WM) in adult patients ...
An application will also be submitted to the European Medicines Agency to extend the marketing authorisation for this age group Pfizer and BioNTech have submitted an application to the US Food and ...